Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">VEGF-C improves regeneration and lymphatic reconnection of transplanted autologous lymph node fragments: An animal model for secondary lymphedema treatment</title><author><name sortKey="Schindewolffs, Lia" sort="Schindewolffs, Lia" uniqKey="Schindewolffs L" first="Lia" last="Schindewolffs">Lia Schindewolffs</name><affiliation><nlm:aff id="au1"><institution>Institute of Immunomorphology, Hannover Medical School</institution><addr-line>Hannover, Niedersachsen, Germany</addr-line></nlm:aff></affiliation></author><author><name sortKey="Breves, Gerhard" sort="Breves, Gerhard" uniqKey="Breves G" first="Gerhard" last="Breves">Gerhard Breves</name><affiliation><nlm:aff id="au2"><institution>Department of Physiology, University of Veterinary Medicine, Foundation Hannover</institution><addr-line>Hannover, Niedersachsen, Germany</addr-line></nlm:aff></affiliation></author><author><name sortKey="Buettner, Manuela" sort="Buettner, Manuela" uniqKey="Buettner M" first="Manuela" last="Buettner">Manuela Buettner</name><affiliation><nlm:aff id="au3"><institution>Institute of Functional and Applied Anatomy, Hannover Medical School</institution><addr-line>Hannover, Niedersachsen, Germany</addr-line></nlm:aff></affiliation></author><author><name sortKey="Hadamitzky, Catarina" sort="Hadamitzky, Catarina" uniqKey="Hadamitzky C" first="Catarina" last="Hadamitzky">Catarina Hadamitzky</name><affiliation><nlm:aff id="au4"><institution>Clinic of Plastic, Hand and Reconstructive Surgery, Hannover Medical School</institution><addr-line>Hannover, Niedersachsen, Germany</addr-line></nlm:aff></affiliation></author><author><name sortKey="Pabst, Reinhard" sort="Pabst, Reinhard" uniqKey="Pabst R" first="Reinhard" last="Pabst">Reinhard Pabst</name><affiliation><nlm:aff id="au1"><institution>Institute of Immunomorphology, Hannover Medical School</institution><addr-line>Hannover, Niedersachsen, Germany</addr-line></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">25505549</idno><idno type="pmc">4257760</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4257760</idno><idno type="RBID">PMC:4257760</idno><idno type="doi">10.1002/iid3.32</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">003F02</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">003F02</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">VEGF-C improves regeneration and lymphatic reconnection of transplanted autologous lymph node fragments: An animal model for secondary lymphedema treatment</title><author><name sortKey="Schindewolffs, Lia" sort="Schindewolffs, Lia" uniqKey="Schindewolffs L" first="Lia" last="Schindewolffs">Lia Schindewolffs</name><affiliation><nlm:aff id="au1"><institution>Institute of Immunomorphology, Hannover Medical School</institution><addr-line>Hannover, Niedersachsen, Germany</addr-line></nlm:aff></affiliation></author><author><name sortKey="Breves, Gerhard" sort="Breves, Gerhard" uniqKey="Breves G" first="Gerhard" last="Breves">Gerhard Breves</name><affiliation><nlm:aff id="au2"><institution>Department of Physiology, University of Veterinary Medicine, Foundation Hannover</institution><addr-line>Hannover, Niedersachsen, Germany</addr-line></nlm:aff></affiliation></author><author><name sortKey="Buettner, Manuela" sort="Buettner, Manuela" uniqKey="Buettner M" first="Manuela" last="Buettner">Manuela Buettner</name><affiliation><nlm:aff id="au3"><institution>Institute of Functional and Applied Anatomy, Hannover Medical School</institution><addr-line>Hannover, Niedersachsen, Germany</addr-line></nlm:aff></affiliation></author><author><name sortKey="Hadamitzky, Catarina" sort="Hadamitzky, Catarina" uniqKey="Hadamitzky C" first="Catarina" last="Hadamitzky">Catarina Hadamitzky</name><affiliation><nlm:aff id="au4"><institution>Clinic of Plastic, Hand and Reconstructive Surgery, Hannover Medical School</institution><addr-line>Hannover, Niedersachsen, Germany</addr-line></nlm:aff></affiliation></author><author><name sortKey="Pabst, Reinhard" sort="Pabst, Reinhard" uniqKey="Pabst R" first="Reinhard" last="Pabst">Reinhard Pabst</name><affiliation><nlm:aff id="au1"><institution>Institute of Immunomorphology, Hannover Medical School</institution><addr-line>Hannover, Niedersachsen, Germany</addr-line></nlm:aff></affiliation></author></analytic><series><title level="j">Immunity, Inflammation and Disease</title><idno type="ISSN">2050-4527</idno><idno type="eISSN">2050-4527</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Secondary lymphedema occurs after for example breast cancer surgery and radiation in 20–50% of the patients. Due to the poor outcomes of surgical treatments in the past, the therapy often remains symptomatic. However, avascular transplantation of autologous lymph node fragments (LN-Tx) combined with postoperative injections of vascular endothelial growth factor-C (VEGF-C) emerges as a potential surgical therapy. In this study, adult rats underwent LN-Tx to investigate the following parameters of VEGF-C application: time point, location and dosage. Furthermore, the influences of VEGF-C on lymphatic reconnection and transplant regeneration were analyzed. The reconnection was investigated using intradermally injected blue dye and the regeneration was evaluated histologically using hematoxylin-eosin (H&E) staining and immunohistochemistry. The higher dosage enhanced the reconnection rates significantly and showed a statistical tendency of improving regeneration. An application on early postoperative days and the injection into the medial thigh improved the reconnection significantly. However, these variables did not affect the regeneration statistically. This study confirms that LN-Tx combined with lymphatic growth factor VEGF-C is a possible approach in the therapy of secondary lymphedema and shows the important role of VEGF-C application parameters.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Bajenoff, M" uniqKey="Bajenoff M">M Bajenoff</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tewalt, Ef" uniqKey="Tewalt E">EF Tewalt</name></author><author><name sortKey="Cohen, Jn" uniqKey="Cohen J">JN Cohen</name></author><author><name sortKey="Rouhani, Sj" uniqKey="Rouhani S">SJ Rouhani</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Girard, Jp" uniqKey="Girard J">JP Girard</name></author><author><name sortKey="Moussion, C" uniqKey="Moussion C">C Moussion</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tammela, T" uniqKey="Tammela T">T Tammela</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wiig, H" uniqKey="Wiig H">H Wiig</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boulpaep, El" uniqKey="Boulpaep E">EL Boulpaep</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hall, Je" uniqKey="Hall J">JE Hall</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Levick, Jr" uniqKey="Levick J">JR Levick</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ohtani, O" uniqKey="Ohtani O">O Ohtani</name></author><author><name sortKey="Ohtani, Y" uniqKey="Ohtani Y">Y Ohtani</name></author><author><name sortKey="Carati, Cj" uniqKey="Carati C">CJ Carati</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Morgan, Pa" uniqKey="Morgan P">PA Morgan</name></author><author><name sortKey="Franks, Pj" uniqKey="Franks P">PJ Franks</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Butler, Mg" uniqKey="Butler M">MG Butler</name></author><author><name sortKey="Dagenais, Sl" uniqKey="Dagenais S">SL Dagenais</name></author><author><name sortKey="Rockson, Sg" uniqKey="Rockson S">SG Rockson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Warren, Ag" uniqKey="Warren A">AG Warren</name></author><author><name sortKey="Brorson, H" uniqKey="Brorson H">H Brorson</name></author><author><name sortKey="Borud, Lj" uniqKey="Borud L">LJ Borud</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pfarr, Km" uniqKey="Pfarr K">KM Pfarr</name></author><author><name sortKey="Debrah, Ay" uniqKey="Debrah A">AY Debrah</name></author><author><name sortKey="Specht, S" uniqKey="Specht S">S Specht</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Goldberg, Ji" uniqKey="Goldberg J">JI Goldberg</name></author><author><name sortKey="Riedel, Er" uniqKey="Riedel E">ER Riedel</name></author><author><name sortKey="Morrow, M" uniqKey="Morrow M">M Morrow</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Williams, Af" uniqKey="Williams A">AF Williams</name></author><author><name sortKey="Franks, Pj" uniqKey="Franks P">PJ Franks</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mortimer, P" uniqKey="Mortimer P">P Mortimer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ferrell, Re" uniqKey="Ferrell R">RE Ferrell</name></author><author><name sortKey="Baty, Cj" uniqKey="Baty C">CJ Baty</name></author><author><name sortKey="Kimak, Ma" uniqKey="Kimak M">MA Kimak</name></author><author><name sortKey="Karlsson, Jm" uniqKey="Karlsson J">JM Karlsson</name></author><author><name sortKey="Lawrence, Ec" uniqKey="Lawrence E">EC Lawrence</name></author><author><name sortKey="Franke Snyder, M" uniqKey="Franke Snyder M">M Franke-Snyder</name></author><author><name sortKey="Meriney, Sd" uniqKey="Meriney S">SD Meriney</name></author><author><name sortKey="Feingold, E" uniqKey="Feingold E">E Feingold</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Finegold, Dn" uniqKey="Finegold D">DN Finegold</name></author><author><name sortKey="Baty, Cj" uniqKey="Baty C">CJ Baty</name></author><author><name sortKey="Knickelbein, Kz" uniqKey="Knickelbein K">KZ Knickelbein</name></author><author><name sortKey="Perschke, S" uniqKey="Perschke S">S Perschke</name></author><author><name sortKey="Noon, Se" uniqKey="Noon S">SE Noon</name></author><author><name sortKey="Campbell, D" uniqKey="Campbell D">D Campbell</name></author><author><name sortKey="Karlsson, Jm" uniqKey="Karlsson J">JM Karlsson</name></author><author><name sortKey="Huang, D" uniqKey="Huang D">D Huang</name></author><author><name sortKey="Kimak, Ma" uniqKey="Kimak M">MA Kimak</name></author><author><name sortKey="Lawrence, Ec" uniqKey="Lawrence E">EC Lawrence</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Leung, G" uniqKey="Leung G">G Leung</name></author><author><name sortKey="Baggott, C" uniqKey="Baggott C">C Baggott</name></author><author><name sortKey="West, C" uniqKey="West C">C West</name></author><author><name sortKey="Elboim, C" uniqKey="Elboim C">C Elboim</name></author><author><name sortKey="Paul, Sm" uniqKey="Paul S">SM Paul</name></author><author><name sortKey="Cooper, Ba" uniqKey="Cooper B">BA Cooper</name></author><author><name sortKey="Abrams, G" uniqKey="Abrams G">G Abrams</name></author><author><name sortKey="Dhruva, A" uniqKey="Dhruva A">A Dhruva</name></author><author><name sortKey="Schmidt, Bl" uniqKey="Schmidt B">BL Schmidt</name></author><author><name sortKey="Kober, K" uniqKey="Kober K">K Kober</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lin, S" uniqKey="Lin S">S Lin</name></author><author><name sortKey="Kim, J" uniqKey="Kim J">J Kim</name></author><author><name sortKey="Lee, Mj" uniqKey="Lee M">MJ Lee</name></author><author><name sortKey="Roche, L" uniqKey="Roche L">L Roche</name></author><author><name sortKey="Yang, Nl" uniqKey="Yang N">NL Yang</name></author><author><name sortKey="Tsao, Ps" uniqKey="Tsao P">PS Tsao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Newman, B" uniqKey="Newman B">B Newman</name></author><author><name sortKey="Lose, F" uniqKey="Lose F">F Lose</name></author><author><name sortKey="Kedda, Ma" uniqKey="Kedda M">MA Kedda</name></author><author><name sortKey="Francois, M" uniqKey="Francois M">M Francois</name></author><author><name sortKey="Ferguson, K" uniqKey="Ferguson K">K Ferguson</name></author><author><name sortKey="Janda, M" uniqKey="Janda M">M Janda</name></author><author><name sortKey="Yates, P" uniqKey="Yates P">P Yates</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Disipio, T" uniqKey="Disipio T">T DiSipio</name></author><author><name sortKey="Rye, S" uniqKey="Rye S">S Rye</name></author><author><name sortKey="Newman, B" uniqKey="Newman B">B Newman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mehrara, Bj" uniqKey="Mehrara B">BJ Mehrara</name></author><author><name sortKey="Zampell, Jc" uniqKey="Zampell J">JC Zampell</name></author><author><name sortKey="Suami, H" uniqKey="Suami H">H Suami</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Suami, H" uniqKey="Suami H">H Suami</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cormier, Jn" uniqKey="Cormier J">JN Cormier</name></author><author><name sortKey="Rourke, L" uniqKey="Rourke L">L Rourke</name></author><author><name sortKey="Crosby, M" uniqKey="Crosby M">M Crosby</name></author><author><name sortKey="Chang, D" uniqKey="Chang D">D Chang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vignes, S" uniqKey="Vignes S">S Vignes</name></author><author><name sortKey="Blanchard, M" uniqKey="Blanchard M">M Blanchard</name></author><author><name sortKey="Yannoutsos, A" uniqKey="Yannoutsos A">A Yannoutsos</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brorson, H" uniqKey="Brorson H">H Brorson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Blum, Ks" uniqKey="Blum K">KS Blum</name></author><author><name sortKey="Hadamitzky, C" uniqKey="Hadamitzky C">C Hadamitzky</name></author><author><name sortKey="Gratz, Kf" uniqKey="Gratz K">KF Gratz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pabst, R" uniqKey="Pabst R">R Pabst</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rothkotter, Hj" uniqKey="Rothkotter H">HJ Rothkotter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tammela, T" uniqKey="Tammela T">T Tammela</name></author><author><name sortKey="Saaristo, A" uniqKey="Saaristo A">A Saaristo</name></author><author><name sortKey="Holopainen, T" uniqKey="Holopainen T">T Holopainen</name></author><author><name sortKey="Lyytikk, J" uniqKey="Lyytikk J">J Lyytikkä</name></author><author><name sortKey="Kotronen, A" uniqKey="Kotronen A">A Kotronen</name></author><author><name sortKey="Pitkonen, M" uniqKey="Pitkonen M">M Pitkonen</name></author><author><name sortKey="Abo Ramadan, U" uniqKey="Abo Ramadan U">U Abo-Ramadan</name></author><author><name sortKey="Yl Herttuala, S" uniqKey="Yl Herttuala S">S Ylä-Herttuala</name></author><author><name sortKey="Petrova, Tv" uniqKey="Petrova T">TV Petrova</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tobbia, D" uniqKey="Tobbia D">D Tobbia</name></author><author><name sortKey="Semple, J" uniqKey="Semple J">J Semple</name></author><author><name sortKey="Baker, A" uniqKey="Baker A">A Baker</name></author><author><name sortKey="Dumont, D" uniqKey="Dumont D">D Dumont</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sommer, T" uniqKey="Sommer T">T Sommer</name></author><author><name sortKey="Buettner, M" uniqKey="Buettner M">M Buettner</name></author><author><name sortKey="Bruns, F" uniqKey="Bruns F">F Bruns</name></author><author><name sortKey="Breves, G" uniqKey="Breves G">G Breves</name></author><author><name sortKey="Hadamitzky, C" uniqKey="Hadamitzky C">C Hadamitzky</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sommer, T" uniqKey="Sommer T">T Sommer</name></author><author><name sortKey="Meier, M" uniqKey="Meier M">M Meier</name></author><author><name sortKey="Bruns, F" uniqKey="Bruns F">F Bruns</name></author><author><name sortKey="Pabst, R" uniqKey="Pabst R">R Pabst</name></author><author><name sortKey="Breves, G" uniqKey="Breves G">G Breves</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schindewolffs, L" uniqKey="Schindewolffs L">L Schindewolffs</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Burton, Jb" uniqKey="Burton J">JB Burton</name></author><author><name sortKey="Priceman, Sj" uniqKey="Priceman S">SJ Priceman</name></author><author><name sortKey="Sung, Jl" uniqKey="Sung J">JL Sung</name></author><author><name sortKey="Brakenhielm, E" uniqKey="Brakenhielm E">E Brakenhielm</name></author><author><name sortKey="An, Ds" uniqKey="An D">DS An</name></author><author><name sortKey="Pytowski, B" uniqKey="Pytowski B">B Pytowski</name></author><author><name sortKey="Alitalo, K" uniqKey="Alitalo K">K Alitalo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Alitalo, K" uniqKey="Alitalo K">K Alitalo</name></author><author><name sortKey="Tammela, T" uniqKey="Tammela T">T Tammela</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liersch, R" uniqKey="Liersch R">R Liersch</name></author><author><name sortKey="Hirakawa, S" uniqKey="Hirakawa S">S Hirakawa</name></author><author><name sortKey="Berdel, We" uniqKey="Berdel W">WE Berdel</name></author><author><name sortKey="Mesters, Rm" uniqKey="Mesters R">RM Mesters</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chang, Xz" uniqKey="Chang X">XZ Chang</name></author><author><name sortKey="Yin, J" uniqKey="Yin J">J Yin</name></author><author><name sortKey="Sun, J" uniqKey="Sun J">J Sun</name></author><author><name sortKey="Zhang, Xh" uniqKey="Zhang X">XH Zhang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dominick, Sa" uniqKey="Dominick S">SA Dominick</name></author><author><name sortKey="Madlensky, L" uniqKey="Madlensky L">L Madlensky</name></author><author><name sortKey="Natarajan, L" uniqKey="Natarajan L">L Natarajan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ul Mulk, J" uniqKey="Ul Mulk J">J Ul-Mulk</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rabson, Ja" uniqKey="Rabson J">JA Rabson</name></author><author><name sortKey="Geyer, Sj" uniqKey="Geyer S">SJ Geyer</name></author><author><name sortKey="Levine, G" uniqKey="Levine G">G Levine</name></author><author><name sortKey="Swartz, Wm" uniqKey="Swartz W">WM Swartz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Turnbull, C" uniqKey="Turnbull C">C Turnbull</name></author><author><name sortKey="Ahmed, S" uniqKey="Ahmed S">S Ahmed</name></author><author><name sortKey="Morrison, J" uniqKey="Morrison J">J Morrison</name></author><author><name sortKey="Pernet, D" uniqKey="Pernet D">D Pernet</name></author><author><name sortKey="Renwick, A" uniqKey="Renwick A">A Renwick</name></author><author><name sortKey="Maranian, M" uniqKey="Maranian M">M Maranian</name></author><author><name sortKey="Seal, S" uniqKey="Seal S">S Seal</name></author><author><name sortKey="Ghoussaini, M" uniqKey="Ghoussaini M">M Ghoussaini</name></author><author><name sortKey="Hines, S" uniqKey="Hines S">S Hines</name></author><author><name sortKey="Healey, Cs" uniqKey="Healey C">CS Healey</name></author><author><name sortKey="Hughes, D" uniqKey="Hughes D">D Hughes</name></author><author><name sortKey="Warren Perry, M" uniqKey="Warren Perry M">M Warren-Perry</name></author><author><name sortKey="Tapper, W" uniqKey="Tapper W">W Tapper</name></author><author><name sortKey="Eccles, D" uniqKey="Eccles D">D Eccles</name></author><author><name sortKey="Evans, Dg" uniqKey="Evans D">DG Evans</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hadamitzky, C" uniqKey="Hadamitzky C">C Hadamitzky</name></author><author><name sortKey="Blum, Ks" uniqKey="Blum K">KS Blum</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lohela, M" uniqKey="Lohela M">M Lohela</name></author><author><name sortKey="Saaristo, A" uniqKey="Saaristo A">A Saaristo</name></author><author><name sortKey="Veikkola, T" uniqKey="Veikkola T">T Veikkola</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pezner, Rd" uniqKey="Pezner R">RD Pezner</name></author><author><name sortKey="Patterson, Mp" uniqKey="Patterson M">MP Patterson</name></author><author><name sortKey="Hill, Lr" uniqKey="Hill L">LR Hill</name></author><author><name sortKey="Lipsett, Ja" uniqKey="Lipsett J">JA Lipsett</name></author><author><name sortKey="Desai, Kr" uniqKey="Desai K">KR Desai</name></author><author><name sortKey="Vora, N" uniqKey="Vora N">N Vora</name></author><author><name sortKey="Wong, Jy" uniqKey="Wong J">JY Wong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hadamitzky, C" uniqKey="Hadamitzky C">C Hadamitzky</name></author><author><name sortKey="Spohr, H" uniqKey="Spohr H">H Spohr</name></author><author><name sortKey="Debertin, As" uniqKey="Debertin A">AS Debertin</name></author><author><name sortKey="Guddat, S" uniqKey="Guddat S">S Guddat</name></author><author><name sortKey="Tsokos, M" uniqKey="Tsokos M">M Tsokos</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Avraham, T" uniqKey="Avraham T">T Avraham</name></author><author><name sortKey="Clavin, Nw" uniqKey="Clavin N">NW Clavin</name></author><author><name sortKey="Daluvoy, Sv" uniqKey="Daluvoy S">SV Daluvoy</name></author><author><name sortKey="Fernandez, J" uniqKey="Fernandez J">J Fernandez</name></author><author><name sortKey="Soares, Ma" uniqKey="Soares M">MA Soares</name></author><author><name sortKey="Cordeiro, Ap" uniqKey="Cordeiro A">AP Cordeiro</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Couto, Ra" uniqKey="Couto R">RA Couto</name></author><author><name sortKey="Kulungowski, Am" uniqKey="Kulungowski A">AM Kulungowski</name></author><author><name sortKey="Chawla, As" uniqKey="Chawla A">AS Chawla</name></author><author><name sortKey="Fishman, Sj" uniqKey="Fishman S">SJ Fishman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ogata, F" uniqKey="Ogata F">F Ogata</name></author><author><name sortKey="Narushima, M" uniqKey="Narushima M">M Narushima</name></author><author><name sortKey="Mihara, M" uniqKey="Mihara M">M Mihara</name></author><author><name sortKey="Azuma, R" uniqKey="Azuma R">R Azuma</name></author><author><name sortKey="Morimoto, Y" uniqKey="Morimoto Y">Y Morimoto</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Polom, K" uniqKey="Polom K">K Polom</name></author><author><name sortKey="Murawa, D" uniqKey="Murawa D">D Murawa</name></author><author><name sortKey="Rho, Ys" uniqKey="Rho Y">YS Rho</name></author><author><name sortKey="Nowaczyk, P" uniqKey="Nowaczyk P">P Nowaczyk</name></author><author><name sortKey="Hunerbein, M" uniqKey="Hunerbein M">M Hunerbein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Serizawa, F" uniqKey="Serizawa F">F Serizawa</name></author><author><name sortKey="Ito, K" uniqKey="Ito K">K Ito</name></author><author><name sortKey="Matsubara, M" uniqKey="Matsubara M">M Matsubara</name></author><author><name sortKey="Sato, A" uniqKey="Sato A">A Sato</name></author><author><name sortKey="Shimokawa, H" uniqKey="Shimokawa H">H Shimokawa</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Immun Inflamm Dis</journal-id><journal-id journal-id-type="iso-abbrev">Immun Inflamm Dis</journal-id><journal-id journal-id-type="publisher-id">iid3</journal-id><journal-title-group><journal-title>Immunity, Inflammation and Disease</journal-title></journal-title-group><issn pub-type="ppub">2050-4527</issn><issn pub-type="epub">2050-4527</issn><publisher><publisher-name>BlackWell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25505549</article-id><article-id pub-id-type="pmc">4257760</article-id><article-id pub-id-type="doi">10.1002/iid3.32</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>VEGF-C improves regeneration and lymphatic reconnection of transplanted autologous lymph node fragments: An animal model for secondary lymphedema treatment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Schindewolffs</surname><given-names>Lia</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="author-notes" rid="fn1">†</xref></contrib><contrib contrib-type="author"><name><surname>Breves</surname><given-names>Gerhard</given-names></name><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Buettner</surname><given-names>Manuela</given-names></name><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name><surname>Hadamitzky</surname><given-names>Catarina</given-names></name><xref ref-type="aff" rid="au4">4</xref></contrib><contrib contrib-type="author"><name><surname>Pabst</surname><given-names>Reinhard</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="corresp" rid="cor1"></xref></contrib><aff id="au1"><label>1</label><institution>Institute of Immunomorphology, Hannover Medical School</institution><addr-line>Hannover, Niedersachsen, Germany</addr-line></aff><aff id="au2"><label>2</label><institution>Department of Physiology, University of Veterinary Medicine, Foundation Hannover</institution><addr-line>Hannover, Niedersachsen, Germany</addr-line></aff><aff id="au3"><label>3</label><institution>Institute of Functional and Applied Anatomy, Hannover Medical School</institution><addr-line>Hannover, Niedersachsen, Germany</addr-line></aff><aff id="au4"><label>4</label><institution>Clinic of Plastic, Hand and Reconstructive Surgery, Hannover Medical School</institution><addr-line>Hannover, Niedersachsen, Germany</addr-line></aff></contrib-group><author-notes><corresp id="cor1"><bold>Correspondence</bold> Prof. Dr. Reinhard Pabst, Institute of Immunomorphology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover, Germany. Tel: +49 511 532 6742; Fax: +49 511 532 8256; E-mail: <email>pabst.reinhard@mh-hannover.de</email></corresp><fn id="fn1"><label>†</label><p>Present address: Institute of Anatomy, University of Veterinary Medicine, Foundation Hannover, Bischofsholer Damm 15, 30173 Hannover, Germany.</p></fn><fn><p><bold>Funding information</bold> This work was supported by the Deutsche Forschungsgemeinschaft and the Gesellschaft der Freunde der Medizinischen Hochschule Hannover e.V.</p></fn><fn><p>The data was partly presented as a poster at the 3rd international Lymphoid Tissue Meeting, Rotterdam, September 15–17, 2013.</p></fn></author-notes><pub-date pub-type="ppub"><month>11</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>17</day><month>11</month><year>2014</year></pub-date><volume>2</volume><issue>3</issue><fpage>152</fpage><lpage>161</lpage><history><date date-type="received"><day>06</day><month>2</month><year>2014</year></date><date date-type="rev-recd"><day>23</day><month>5</month><year>2014</year></date><date date-type="accepted"><day>02</day><month>7</month><year>2014</year></date></history><permissions><copyright-statement>© 2014 The Authors. <italic>Immunity, Inflammation and Disease</italic> Published by John Wiley & Sons Ltd.</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Secondary lymphedema occurs after for example breast cancer surgery and radiation in 20–50% of the patients. Due to the poor outcomes of surgical treatments in the past, the therapy often remains symptomatic. However, avascular transplantation of autologous lymph node fragments (LN-Tx) combined with postoperative injections of vascular endothelial growth factor-C (VEGF-C) emerges as a potential surgical therapy. In this study, adult rats underwent LN-Tx to investigate the following parameters of VEGF-C application: time point, location and dosage. Furthermore, the influences of VEGF-C on lymphatic reconnection and transplant regeneration were analyzed. The reconnection was investigated using intradermally injected blue dye and the regeneration was evaluated histologically using hematoxylin-eosin (H&E) staining and immunohistochemistry. The higher dosage enhanced the reconnection rates significantly and showed a statistical tendency of improving regeneration. An application on early postoperative days and the injection into the medial thigh improved the reconnection significantly. However, these variables did not affect the regeneration statistically. This study confirms that LN-Tx combined with lymphatic growth factor VEGF-C is a possible approach in the therapy of secondary lymphedema and shows the important role of VEGF-C application parameters.</p></abstract><kwd-group><kwd>autologous transplantation</kwd><kwd>lymph nodes</kwd><kwd>rat</kwd><kwd>secondary lymphedema</kwd><kwd>VEGF-C</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>The lymphatic system plays an important role in the human body. On the one hand, it is responsible for large parts of the immune defense. Invader antigens are phagocytized by macrophages for direct elimination and also picked up by dendritic cells (DC) for antigen presentation. These antigen-loaded DC are transported into regional lymph nodes (LN) through the lymphatic system. As secondary lymphoid organs, LN host immune cells such as the cortically located B-lymphocytes and the paracortically located T-lymphocytes. Therefore, activation of lymphocytes through DC also takes place in the LN. Due to the cell trafficking through the LN, the histological architecture is essential for its function. Recently, the histotopographic localization of immune cells as well as lymphatic endothelial cells and its relevance for the cellular transport within the LN have been described [<xref rid="b1" ref-type="bibr">1</xref>,<xref rid="b2" ref-type="bibr">2</xref>] and excellently reviewed [<xref rid="b3" ref-type="bibr">3</xref>].</p><p>On the other hand, the lymphatic vessels collect accumulated interstitial fluid and are therefore responsible for the regulation of tissue fluid homeostasis [<xref rid="b4" ref-type="bibr">4</xref>]. Exact data on lymph flow in individual tissues is not available from studies in humans or animals. This is mainly due to problems of methodology and varied techniques of quantitative lymph collection [<xref rid="b5" ref-type="bibr">5</xref>]. The overall lymph flow in humans has been estimated to range between 2 L [<xref rid="b6" ref-type="bibr">6</xref>,<xref rid="b7" ref-type="bibr">7</xref>] and up to 8 L [<xref rid="b8" ref-type="bibr">8</xref>] per day. Some of the fluid is reabsorbed by initial lymphatics. However, since the lymph osmolarity is lower in the afferent lymphatics than in the efferent [<xref rid="b9" ref-type="bibr">9</xref>], most of it seems to be returned to the blood system within the LN. Ohtani et al. [<xref rid="b9" ref-type="bibr">9</xref>] assumed that high endothelial venules (HEV) are responsible for this fluid resorption.</p><p>Considering the amount of accumulating fluid, the need for a functional lymphatic system, and especially functional LN, is obvious. Disturbances can lead to an imbalance of fluid homeostasis and therefore cause accumulation of lymph in the extracellular space: lymphedema, a condition in which the quality of life is greatly restricted and patients experience pain, immobility and poor body image [<xref rid="b10" ref-type="bibr">10</xref>]. Primary causes of lymphedema are genetic disorders such as Milroy Disease, which is caused by a mutation of the VEGF-receptor-3 (VEGFR3) and results in a hypoplasia of the lymphatics and a primary lymphedema [<xref rid="b11" ref-type="bibr">11</xref>,<xref rid="b12" ref-type="bibr">12</xref>]. Secondary causes are more prevalent and can be the consequence of bacterial or parasitic (filarial) infections [<xref rid="b13" ref-type="bibr">13</xref>] or the surgical removal of LN and lymphatics, for example, during axillary LN dissection (ALND) due to breast cancer. Since sentinel lymph node biopsy (SLNB) developed as the method of choice for the axillary staging of women with early breast cancer [<xref rid="b14" ref-type="bibr">14</xref>], fewer patients require ALND. However, ALND is still indicated when metastases are present. After ALND, up to 30% of the patients develop secondary lymphedema [<xref rid="b15" ref-type="bibr">15</xref>]. After SLNB up to 22% of patients still suffer from arm swelling and lymphedema [<xref rid="b14" ref-type="bibr">14</xref>], consequently incidence rates remain high, as very recently pointed out [<xref rid="b16" ref-type="bibr">16</xref>]. Despite invasive surgical interventions, several risk factors, especially genetic dispositions [<xref rid="b17" ref-type="bibr">17</xref>–<xref rid="b21" ref-type="bibr">21</xref>], a high body-mass index and low physical activity, additionally increase the occurrence of secondary lymphedema [<xref rid="b22" ref-type="bibr">22</xref>].</p><p>Most of the surgical techniques, such as lymphatic bypasses and flap interpositions did not show convincing long-term effects [<xref rid="b23" ref-type="bibr">23</xref>–<xref rid="b25" ref-type="bibr">25</xref>]. Vignes et al. [<xref rid="b26" ref-type="bibr">26</xref>] recently stressed the high rate of complications when autologous lymph nodes with surrounding fat tissue were transplanted, although it was performed in a specialized medical center. An exception is liposuction in late-stage lymphedema, resulting in long-term positive effects when performed in a specialized clinic [<xref rid="b27" ref-type="bibr">27</xref>].</p><p>Thus, secondary lymphedema therapy often remains symptomatic. However, the transplantation of autologous LN (LN-Tx), which has already been investigated in pigs [<xref rid="b28" ref-type="bibr">28</xref>–<xref rid="b30" ref-type="bibr">30</xref>] mice [<xref rid="b31" ref-type="bibr">31</xref>], sheep [<xref rid="b32" ref-type="bibr">32</xref>] and rats [<xref rid="b33" ref-type="bibr">33</xref>], appears to be a potential surgical therapy and additional applications of VEGF-C revealed beneficial effects [<xref rid="b31" ref-type="bibr">31</xref>,<xref rid="b33" ref-type="bibr">33</xref>]. Recently, Sommer et al. [<xref rid="b34" ref-type="bibr">34</xref>] developed an adequate animal model for lymphedema and explored the effects of VEGF-C with promising results regarding the reconnection and regeneration of LN [<xref rid="b33" ref-type="bibr">33</xref>]. However, the question whether the results (reconnection of transplanted LN with the lymphatic system and histological regeneration of transplanted LN) can be influenced by the application parameters remained. Therefore, our study was based on the animal model used by Sommer et al. [<xref rid="b34" ref-type="bibr">34</xref>] and we changed the following application parameters: time point, location and dosage. Further details have been described [<xref rid="b35" ref-type="bibr">35</xref>]. The aim was to analyze the influences of these parameters on the reconnection of the transplants with the lymphatic system as well as the histological regeneration of the LN architecture. Adequately integrated LN with a natural histological structure are required for normal lymph drainage and the groundwork for further research in the field of LN-Tx. The results of our study are impressively demonstrating the relevance of application parameter modification and provide essential data for following LN-Tx studies.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><sec><title>Experimental animals</title><p>The experimental procedure had been approved by the local authorities (no. 33.9-42502-04-07/1420). For this study, 109 adult female Lewis rats (LEW/Crl, approximately 200 g) were used. The rats were divided into six groups (A–F). Groups A, B, E, and F included 20 rats, group C 10 rats, and group D 19 rats (<xref ref-type="fig" rid="fig01">Fig. 1</xref>).</p><fig id="fig01" position="float"><label>Figure 1</label><caption><p>Experimental protocol. In every group one VEGF-C application parameter, such as time point, location or dosage was modified. Group A was left without further intervention after surgery (control group) and group B was treated with 240 µL saline solution (saline control group). VEGF-C, vascular endothelial growth factor-C.</p></caption><graphic xlink:href="iid30002-0152-f1"></graphic></fig><p>The animals were housed in groups of 5 under specific pathogen free conditions with a 14 h light and 10 h darkness rhythm and were offered total pathogen free nutrition and osmosis filtered water ad libitum.</p></sec><sec><title>Transplantation procedure</title><p>All rats underwent isoflurane anesthesia (Isofluran Baxter, Baxter Deutschland GmbH, Unterschleißheim, Germany) after one week of acclimatization and an analgesia injection of 5 mg/kg Carprofen subcutaneously (Rimadyl®, Pfizer GmbH, Karlsruhe, Germany) 30 min prior to surgery. In order to simulate the lesions occurring during breast cancer related lymph node dissection, all draining lymph nodes of one limb were eliminated. Accordingly, all popliteal and inguinal LN on the right side were removed. Three inguinal LN were harvested and cut-off one pole each in order to fragment the transplant. Afterwards, non-absorbable suture (Prolene, 5-0, Ethicon GmbH, Norderstedt, Germany) was used to fix them to the subcutaneous tissue. Therefore, the subcutaneous fat tissue was punctured, all three transplants were stringed to the suture and the tissue was punctured again, thus the suture knots and the transplants were separated by subcutaneous fat tissue. The inguinal and popliteal incisions were closed subcutaneously and with skin stitches using absorbable suture (Marlin® violett 5/0, Catgut GmbH, Markneukirchen, Germany). The animals received 5 mg/kg Carprofen subcutaneously 3 days following surgery.</p></sec><sec><title>Groups</title><p>Group A (<italic>n</italic> = 20) functioned as a control group and was left without further intervention after surgery (<xref ref-type="fig" rid="fig01">Fig. 1</xref>). The rats in the saline control group (group B, <italic>n</italic> = 20) were given 240 µL saline solution on postoperative days 1, 2, 3 intradermally into the medial side of the thigh (<xref ref-type="fig" rid="fig01">Fig. 1</xref>). Groups C (<italic>n</italic> = 10) and D (<italic>n</italic> = 19) were treated with 6.67 µg VEGF-C (VEGF-C rr, ReliaTech GmbH, Wolfenbüttel, Germany) on postoperative days 1, 2, 3 but whereas group C was injected intradermally into the abdominal wall, group D was injected intradermally into the right medial thigh (<xref ref-type="fig" rid="fig01">Fig. 1</xref>).</p><p>In Group E (<italic>n</italic> = 20) each rat received an injection of 6.67 µg VEGF-C intradermally into the right medial side of the thigh on postoperative days 14, 15, 16 and group F (<italic>n</italic> = 20) was treated as Group D but with an injection of 13.34 µg VEGF-C per rat on postoperative days 1, 2, 3 (<xref ref-type="fig" rid="fig01">Fig. 1</xref>). In this group one sample was not evaluated immunohistochemically for technical reasons. All groups were evaluated by the same person (LS) in a blind study.</p></sec><sec><title>Sampling</title><p>After a period of 4 weeks, the rats were anesthetized with 90 mg/kg ketamine (Ketamin Gräub, Albrecht GmbH, Aulendorf, Germany) and 10 mg/kg xylazine (Rompun®, Bayer Health Care, Leverkusen, Germany) intraperitoneally. A small amount of blue dye (100–300 µL) (Patentblau V, Gerbet GmbH, Sulzbach, Germany) was injected intradermally into the medial right thigh. In order to stimulate the lymphatic flow, extension, and flexion movements as well as gentle massages of the right hind leg were performed for 1–2 min. The rats were sacrificed by cervical dislocation. A major skin cut was made and the skin was spaciously detached to obtain an adequate overview of the distribution and staining of the lymphatics and transplants. The reconnection was evaluated as successful when blue stained afferent and efferent lymphatics were leading to an equally stained transplant (<xref ref-type="fig" rid="fig02">Fig. 2</xref>).</p><fig id="fig02" position="float"><label>Figure 2</label><caption><p>Lymphatic reconnection. (a) Blue stained afferent and efferent lymphatics (black arrows). The transplant, marked with non-absorbable suture (white arrow), is hidden under fat tissue. (b) Stained transplant after removal.</p></caption><graphic xlink:href="iid30002-0152-f2"></graphic></fig></sec><sec><title>Histochemistry</title><p>After removal, the specimens were frozen in liquid nitrogen and 5 µm slices were made of each sample. H&E staining was used for an overview of the LN structure and distribution of lymphocytes. For proper cell identification and hence in order to specify whether a transplant was histologically regenerated, we additionally performed immunofluorescent staining. Therefore, primary and secondary antibodies were used to detect T-lymphocytes, B-lymphocytes, HEV, and lymphatic endothelial cells (Table<xref ref-type="table" rid="tbl1">1</xref>). The classification in regenerated LN and not regenerated LN was made according to the existence of the aforementioned lymphocytes (B- and T-cells) and endothelial structures (HEV) as well as the physiological distribution of these cells forming the architecture of the LN.</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p>Primary and secondary antibodies used</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Detected cell</th><th align="center" rowspan="1" colspan="1">Primary antibodies</th><th align="center" rowspan="1" colspan="1">Company</th><th align="center" rowspan="1" colspan="1">Species</th><th align="center" rowspan="1" colspan="1">Monoclonal</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">B-lymphocytes</td><td align="left" rowspan="1" colspan="1">BM 4013</td><td align="left" rowspan="1" colspan="1">Acris antibodies, Herford, Germany</td><td align="left" rowspan="1" colspan="1">Mouse</td><td align="center" rowspan="1" colspan="1">×</td></tr><tr><td align="left" rowspan="1" colspan="1">T-lymphocytes</td><td align="left" rowspan="1" colspan="1">R73 FITC (inkcl. sec. AB)</td><td align="left" rowspan="1" colspan="1">AbD serotec, Düsseldorf, Germany</td><td align="left" rowspan="1" colspan="1">Mouse</td><td align="center" rowspan="1" colspan="1">×</td></tr><tr><td align="left" rowspan="1" colspan="1">Lymphatic endothelial cells</td><td align="left" rowspan="1" colspan="1">LYVE-1</td><td align="left" rowspan="1" colspan="1">Relia Tech GmbH, Wolfenbüttel, Germany</td><td align="left" rowspan="1" colspan="1">Rabbit</td><td align="center" rowspan="1" colspan="1">×</td></tr><tr><td align="left" rowspan="1" colspan="1">HEV</td><td align="left" rowspan="1" colspan="1">HIS 52</td><td align="left" rowspan="1" colspan="1">Abcam, Cambrige, USA</td><td align="left" rowspan="1" colspan="1">Mouse</td><td align="center" rowspan="1" colspan="1">×</td></tr><tr><td rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">Secondary antibodies</td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1">Polyclonal</td></tr><tr><td align="left" rowspan="1" colspan="1">Lymphatic endothelial cells</td><td align="left" rowspan="1" colspan="1">CY™3</td><td align="left" rowspan="1" colspan="1">Dianova GmbH, Hamburg, Germany</td><td align="left" rowspan="1" colspan="1">Goat anti rabbit</td><td align="center" rowspan="1" colspan="1">×</td></tr><tr><td align="left" rowspan="1" colspan="1">HEV</td><td align="left" rowspan="1" colspan="1">AF 546</td><td align="left" rowspan="1" colspan="1">Invitrogen GmbH, Darmstadt, Germany</td><td align="left" rowspan="1" colspan="1">Goat anti mouse</td><td align="center" rowspan="1" colspan="1">×</td></tr></tbody></table></table-wrap></sec><sec><title>Statistics</title><p>For statistical evaluation, <italic>GraphPad Prism</italic> (5.02, GraphPad Software, La Jolla, CA, USA) was used. The groups were combined in different ways (Table<xref ref-type="table" rid="tbl2">2</xref>) to analyze the parameters time point, location and dosage with the Fisher's Exact Test. Thus, <italic>P</italic>-values of 0.05 < <italic>P</italic> < 0.10 showed a statistical tendency, a result with <italic>P</italic>-values of <0.05 was significant, with <italic>P</italic> < 0.01 highly significant and with <italic>P</italic> < 0.001 extremely significant.</p><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p>Group constellations for statistical purposes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Investigated parameter</th><th align="center" rowspan="1" colspan="1">Statistically combined groups</th><th align="center" rowspan="1" colspan="1">Time point</th><th align="center" rowspan="1" colspan="1">Dosage</th><th align="center" rowspan="1" colspan="1">Location</th></tr></thead><tbody><tr><td align="left" rowspan="4" valign="top" colspan="1">Time point</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" colspan="3" rowspan="1">No intervention after LN-Tx</td></tr><tr><td align="center" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">Postoperative days 1, 2, 3</td><td align="left" rowspan="1" colspan="1">240 μL saline solution lC</td><td align="left" rowspan="1" colspan="1">Medial thigh</td></tr><tr><td align="center" rowspan="1" colspan="1">D</td><td align="left" rowspan="1" colspan="1">Postoperative days 1, 2, 3</td><td align="left" rowspan="1" colspan="1">6.67 μg VEGF-ClC</td><td align="left" rowspan="1" colspan="1">Medial thigh</td></tr><tr><td align="center" rowspan="1" colspan="1">E</td><td align="left" rowspan="1" colspan="1">Postoperative days 14, 15, 16</td><td align="left" rowspan="1" colspan="1">6.67 μg VEGF-ClC</td><td align="left" rowspan="1" colspan="1">Medial thigh</td></tr><tr><td align="left" rowspan="4" valign="top" colspan="1">Location</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" colspan="3" rowspan="1">No intervention after LN-Tx</td></tr><tr><td align="center" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">Postoperative days 1, 2, 3</td><td align="left" rowspan="1" colspan="1">240 μL saline solution lC</td><td align="left" rowspan="1" colspan="1">Medial thigh</td></tr><tr><td align="center" rowspan="1" colspan="1">C</td><td align="left" rowspan="1" colspan="1">Postoperative days 1, 2, 3</td><td align="left" rowspan="1" colspan="1">6.67 μL VEGF-ClC</td><td align="left" rowspan="1" colspan="1">Abdominal wall</td></tr><tr><td align="center" rowspan="1" colspan="1">D</td><td align="left" rowspan="1" colspan="1">Postoperative days 1, 2, 3</td><td align="left" rowspan="1" colspan="1">6.67 μg VEGF-ClC</td><td align="left" rowspan="1" colspan="1">Medial thigh</td></tr><tr><td align="left" rowspan="4" valign="top" colspan="1">Dosage</td><td align="center" rowspan="1" colspan="1">A</td><td align="center" colspan="3" rowspan="1">No intervention after LN-Tx</td></tr><tr><td align="center" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">Postoperative days 1, 2, 3</td><td align="left" rowspan="1" colspan="1">240 μL saline solution lC</td><td align="left" rowspan="1" colspan="1">Medial thigh</td></tr><tr><td align="center" rowspan="1" colspan="1">D</td><td align="left" rowspan="1" colspan="1">Postoperative days 1, 2, 3</td><td align="left" rowspan="1" colspan="1">6.67 μg VEGF-ClC</td><td align="left" rowspan="1" colspan="1">Medial thigh</td></tr><tr><td align="center" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">Postoperative days 1, 2, 3</td><td align="left" rowspan="1" colspan="1">13.34 μg VEGF-ClC</td><td align="left" rowspan="1" colspan="1">Medial thigh</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Reconnection of the transplants with lymphatic collectors</title><p>The injection of blue dye allowed the examination of the integrity of the previously damaged lymphatic system in the upper hind leg and inguinal region (<xref ref-type="fig" rid="fig02">Fig. 2</xref>). Only reconnected transplants are able to receive intradermally injected blue dye via the reconnected lymphatic vessels. Transplants which were not reconnected were not stained at all.</p><p>In the control group (group A) 15% and in the saline control group (group B) 10% of the rats showed a reconnection of the transplants with the lymphatics. Group C (early application, 6.67 µg VEGF-C, abdominal wall) presented a rate of 50% reconnected transplants and group D (early application, 6.67 µg VEGF-C, medial thigh) a rate of 53%. In group E (late application, 6.67 µg VEGF-C, medial thigh) there were 35% of the rats and in group F (early application of 13.34 µg VEGF-C, medial thigh) 85% presenting reconnected transplants.</p><p>In terms of the time point, the analysis of group A (control) and group D showed a statistical significance. The comparison between group B and group D was highly significant. The comparison between group A (control) and group E (late application, 6.67 µg VEGF-C, medial thigh) as well as between group D (saline control) and E presented no relevant statistical difference (<xref ref-type="fig" rid="fig03">Fig. 3</xref>).</p><fig id="fig03" position="float"><label>Figure 3</label><caption><p>Lymphatic reconnection of transplants and statistical significances.</p></caption><graphic xlink:href="iid30002-0152-f3"></graphic></fig><p>Regarding the location, a statistical tendency was shown between group A (control) and group C (early application, 6.67 µg VEGF-C, abdominal wall) and a statistical significance between group B (saline control) and C as well as between group A (control) and group D (early application, 6.67 µg VEGF-C, medial thigh) (<xref ref-type="fig" rid="fig03">Fig. 3</xref>).</p><p>The group comparison to investigate dosage influences revealed the following results: Group A (control) and B (saline control) compared to group F (early application, 13.34 µg VEGF-C, medial thigh) showed an extremely significant effect and group A compared to group D presented a statistical significance. The comparison between group D and F also showed a statistical significance (<xref ref-type="fig" rid="fig03">Fig. 3</xref>).</p></sec><sec><title>Regeneration of transplants</title><p>In order to differentiate between necrotic transplants and potentially regenerated ones, H&E staining was performed (<xref ref-type="fig" rid="fig04">Fig. 4</xref>a and b). All of the potentially regenerated transplants had been prepared for immunohistochemistry to examine the distribution of the B- and T-cells (<xref ref-type="fig" rid="fig04">Fig. 4</xref>c–e) as well as the presence of lymphatic endothelial cells (<xref ref-type="fig" rid="fig04">Fig. 4</xref>f and g) and HEV (<xref ref-type="fig" rid="fig04">Fig. 4</xref>h and i) in order to assess whether a transplant was histologically regenerated or not.</p><fig id="fig04" position="float"><label>Figure 4</label><caption><p>H&E staining and immunohistochemistry. (a and b) H&E staining of a necrotic (a) and a potential regenerated (b) transplant. (c–i) Regenerated transplant after immunohistochemistry. (c–e) Primary antibodies used against T-lymphocytes (R73) and B-lymphocytes (BM 4013) and immunofluorescent secondary antibodies FITC and AF564. (c) T-lymphocytes are located paracortically. (d) B-lymphocytes are located cortically. (e) Merged image. (f and g) Primary antibody used against lymphatic endothelial cells (LYVE-1) and immunofluorescent secondary antibody Cy3. (h and i) Primary antibody used against high endothelial venules (His52) and immunofluorescent secondary antibody AF546. H&E, hematoxylin and eosin.</p></caption><graphic xlink:href="iid30002-0152-f4"></graphic></fig><p>In the control group (group A) and in the saline control group (group B) 70% of the rats showed regenerated transplants. Group C (early application, 6.67 µg VEGF-C, abdominal wall) presented a rate of 80% rats with regenerated transplants, group D (early application, 6.67 µg VEGF-C, medial thigh) 89%, group E (late application, 6.67 µg VEGF-C, medial thigh) 85% and group F (early application, 13.34 µg VEGF-C, medial thigh) 95%.</p><p>Regarding the time point, none of the comparisons (control groups A and B, group D and E) showed any statistical relevance (<xref ref-type="fig" rid="fig05">Fig. 5</xref>) and the analysis of the parameter location (control group A and B, group C and D) revealed no statistical relevance either (<xref ref-type="fig" rid="fig05">Fig. 5</xref>).</p><fig id="fig05" position="float"><label>Figure 5</label><caption><p>Transplant regeneration and statistical significances.</p></caption><graphic xlink:href="iid30002-0152-f5"></graphic></fig><p>In terms of the dosage however, the comparison between group A (control) and group F (early application, 13.34 µg VEGF-C, medial thigh) as well as between group B (saline control) and group F showed a statistical tendency, but the difference between the control groups (A and B) and group D and between group F and D showed no statistical relevance (<xref ref-type="fig" rid="fig05">Fig. 5</xref>).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The most common causes for secondary lymphedema in industrialized countries are oncologic surgery and radiation. Prostate [<xref rid="b36" ref-type="bibr">36</xref>] and penis cancer in men, cervical, genital and breast cancer [<xref rid="b37" ref-type="bibr">37</xref>] in women, but also melanoma of the extremities [<xref rid="b38" ref-type="bibr">38</xref>], are examples of high prevalence tumors with a tendency for lymphatic metastasis. To address these malignancies, the removal and/or radiation of axillary/inguinal draining lymph nodes has proved to be an important prognostic factor [<xref rid="b39" ref-type="bibr">39</xref>]. Nevertheless, this therapy also deprives the operated areas of their local immune defenses, located in the removed/irradiated lymph nodes. Additionally, 20–50% of these patients develop secondary lymphedema [<xref rid="b15" ref-type="bibr">15</xref>,<xref rid="b40" ref-type="bibr">40</xref>,<xref rid="b41" ref-type="bibr">41</xref>]. LN-Tx of autologous donor lymph nodes, not primarily involved in the tumor drainage area (“clean” nodes), seems to benefit the lymphatic drainage of the receptor area and could potentially be used as a solution for secondary lymphedema. Interestingly, transplanted lymph nodes also have been proven to regain their immune function, including being able to trap tumor cells [for Review see [<xref rid="b42" ref-type="bibr">42</xref>]]. Thus, in case of recurrence of the primary malignancy, LN-Tx yields potential benefits in the protection of systemic metastasis by regaining local immune and filtering function, in addition to the potential improvement of lymphedema.</p><p>There are also new findings of genetic causes of breast cancer susceptibility [<xref rid="b43" ref-type="bibr">43</xref>] and recent studies documented that lymphedema predisposition after breast cancer surgery can be associated with genetic mutations as well [<xref rid="b17" ref-type="bibr">17</xref>–<xref rid="b21" ref-type="bibr">21</xref>]. Most surgical interventions for lymphedema management deliver no long-term success [<xref rid="b23" ref-type="bibr">23</xref>,<xref rid="b24" ref-type="bibr">24</xref>], further efforts should be made to understand if LN-Tx could be a potential solution as former publications indicate [<xref rid="b28" ref-type="bibr">28</xref>–<xref rid="b33" ref-type="bibr">33</xref>,<xref rid="b44" ref-type="bibr">44</xref>]. Intradermal application of VEGF-C combined with LN-Tx revealed a beneficial effect on the transplant regeneration and the recovery of the lymphatic integrity [<xref rid="b33" ref-type="bibr">33</xref>].</p><p>This procedure was tested on several animal model, such as pigs [<xref rid="b28" ref-type="bibr">28</xref>–<xref rid="b30" ref-type="bibr">30</xref>], mice [<xref rid="b31" ref-type="bibr">31</xref>], sheep [<xref rid="b32" ref-type="bibr">32</xref>], and rats [<xref rid="b33" ref-type="bibr">33</xref>]. Recently, Sommer et al. [<xref rid="b34" ref-type="bibr">34</xref>] developed an adequate animal model for lymphedema and explored the effects of VEGF-C application [<xref rid="b33" ref-type="bibr">33</xref>]. Their study supported promising results regarding the reconnection and histological regeneration of LN [<xref rid="b33" ref-type="bibr">33</xref>].</p><p>Our animal model was based on the recently established techniques [<xref rid="b33" ref-type="bibr">33</xref>] and the outcomes of our study answer the question on how reconnection of transplanted LN within the lymphatic system and histological regeneration of transplanted LN can be influenced by VEGF-C application parameters.</p><p>The reconnection of the transplants to the lymphatic system is the prerequisite to regenerate the possibility for adequate drainage of the limb. The results of this study showed that, regarding the time point, an early application (postoperative days 1, 2, 3) benefits the reconnection significantly in comparison with a late time point (postoperative days 14, 15, 16) (<xref ref-type="fig" rid="fig03">Fig. 3</xref>). Although the VEGF-C treatment itself significantly enhanced the reconnection rate, the location did not seem to influence it (<xref ref-type="fig" rid="fig03">Fig. 3</xref>). Nevertheless, because of the better <italic>P</italic> values (data not shown) an application into the medial thigh is recommended. Reconnection rates proved to be highly VEGF-C dosage dependent. A high dosage of 13.34 µg enhanced the result highly significantly and also showed a significant advantage over an injection of only 6.67 µg (<xref ref-type="fig" rid="fig03">Fig. 3</xref>).</p><p>Additionally to the reconnection of the lymphatics, the proper histological regeneration of the LN architecture is essential to create a functional system for efficient lymph drainage. Although the results regarding regeneration of the transplants are less significant than the ones regarding the reconnection, there are some important aspects: time point and location did not present any statistical relevance (<xref ref-type="fig" rid="fig05">Fig. 5</xref>), though the better <italic>P</italic>-values (data not shown) also indicate that an early time point and an intradermal application into the medial thigh would be the better option. A high dosage, however, showed a statistical tendency, whereas the lower one did not show any statistically relevant effect. Taken together, in this study an early application on postoperative days 1, 2, 3 of 13.34 µg VEGF-C in the medial thigh improved the reconnection and regeneration of autologous LN transplants. Hence, our work points out the importance of the VEGF-C application parameters when performing LN-Tx. However, to gain more information, the dosage should be tested more intensively. Although in this study no macroscopic changes of the neighbored tissue and/or leakiness of the blood vessels was seen, it is described that this can be a side effect of high VEGF-C dosages [<xref rid="b45" ref-type="bibr">45</xref>] and should therefore be investigated in further experiments.</p><p>In our study, young and healthy animals were used. As a model for the clinical situation, older animals are recommended for future experiments, because most patients developing secondary lymphedema are over 60 years old [<xref rid="b46" ref-type="bibr">46</xref>]. Furthermore, in humans the LN of older individuals show some histological changes. Although the general architecture is still present, generalized degeneration and less demarcated T- and B-zones have been described [<xref rid="b47" ref-type="bibr">47</xref>]. We used healthy rats, as we conceived LN-Tx as a possible preventive surgical procedure of lymphedema after breast cancer treatment. This was based on the information that fibrosis is common in chronic lymphedema [<xref rid="b10" ref-type="bibr">10</xref>] and therefore the proliferation of lymph endothelial cells is disturbed [<xref rid="b48" ref-type="bibr">48</xref>], which means that vasculogenesis is likely not involved in the pathogenesis of lymphedema [<xref rid="b49" ref-type="bibr">49</xref>]. Studies to investigate the effects of LN-Tx in chronic lymphedema are required.</p><p>Another aspect, which remained unexplored is the lymph drainage efficiency of the animal model over an extended time period of more than 4 weeks. For that purpose, a possible method would be the use of indocyanine green (ICG) in combination with an imaging unit, such as the photodynamic eye built by Hamamatsu Photonics in Japan. ICG is a fluorescent substance which is already used on humans for example for SLN detection [<xref rid="b50" ref-type="bibr">50</xref>,<xref rid="b51" ref-type="bibr">51</xref>]. Complications with ICG are rare (0.17%) [<xref rid="b50" ref-type="bibr">50</xref>] and it can be used repeatedly on one living individual. Serizawa et al. [<xref rid="b52" ref-type="bibr">52</xref>] successfully tested this method on a tail model of lymphedema in rats.</p><p>Due to the recent developments in research regarding genetic dispositions of most of the secondary lymphedema patients [<xref rid="b17" ref-type="bibr">17</xref>–<xref rid="b21" ref-type="bibr">21</xref>], we plan the first clinical trial in women with extremely increased likelihood of secondary lymphedema. Our study emphasizes the functionality of VEGF-C associated LN-Tx and confirms that VEGF-C generally has a beneficial impact on the histological regeneration and lymphatic reconnection of the transplants. Moreover, it provides fundamental data for an efficient surgical procedure so that the possibility to establish a long-term surgical treatment for secondary lymphedema becomes more and more concrete.</p></sec></body><back><ack><p>The authors thank Sheila Fryk for polishing the English, Sabine Buhmann and Silke Wallbaum for secretarial support and Cornelia Höpfel as well as Susanne Faßbender for excellent technical assistance.</p></ack><sec><title>Conflict of Interest</title><p>None declared.</p></sec><ref-list><title>References</title><ref id="b1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajenoff</surname><given-names>M</given-names></name></person-group><article-title>Stromal cells control soluble material and cellular transport in lymph nodes</article-title><source>Front Immunol</source><year>2012</year><volume>3</volume><fpage>304</fpage><pub-id pub-id-type="pmid">23060882</pub-id></element-citation></ref><ref id="b2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tewalt</surname><given-names>EF</given-names></name><name><surname>Cohen</surname><given-names>JN</given-names></name><name><surname>Rouhani</surname><given-names>SJ</given-names></name></person-group><person-group person-group-type="author"><name><surname>Engelhard</surname><given-names>VH</given-names></name></person-group><article-title>Lymphatic endothelial cells: key players in regulation of tolerance and immunity</article-title><source>Front Immunol</source><year>2012</year><volume>3</volume><fpage>305</fpage><comment>and</comment><pub-id pub-id-type="pmid">23060883</pub-id></element-citation></ref><ref id="b3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girard</surname><given-names>JP</given-names></name><name><surname>Moussion</surname><given-names>C</given-names></name></person-group><person-group person-group-type="author"><name><surname>Forster</surname><given-names>R</given-names></name></person-group><article-title>HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes</article-title><source>Nat. Rev. Immunol</source><year>2012</year><volume>12</volume><fpage>762</fpage><lpage>773</lpage><comment>and</comment><pub-id pub-id-type="pmid">23018291</pub-id></element-citation></ref><ref id="b4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tammela</surname><given-names>T</given-names></name></person-group><person-group person-group-type="author"><name><surname>Alitalo</surname><given-names>K</given-names></name></person-group><article-title>Lymphangiogenesis: molecular mechanisms and future promise</article-title><source>Cell</source><year>2010</year><volume>140</volume><fpage>460</fpage><lpage>476</lpage><comment>and</comment><pub-id pub-id-type="pmid">20178740</pub-id></element-citation></ref><ref id="b5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiig</surname><given-names>H</given-names></name></person-group><person-group person-group-type="author"><name><surname>Swartz</surname><given-names>MA</given-names></name></person-group><article-title>Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer</article-title><source>Physiol. Rev</source><year>2012</year><volume>92</volume><fpage>1005</fpage><lpage>1060</lpage><comment>and</comment><pub-id pub-id-type="pmid">22811424</pub-id></element-citation></ref><ref id="b6"><label>6</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Boulpaep</surname><given-names>EL</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Boron</surname><given-names>WF</given-names></name></person-group><article-title>The microcirculation</article-title><source>Medical Physiology</source><year>2011</year><publisher-loc>Philadelphia</publisher-loc><publisher-name>Saunders, Elsevier</publisher-name><fpage>482</fpage><lpage>503</lpage><comment>ed..</comment></element-citation></ref><ref id="b7"><label>7</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>JE</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Guyton</surname><given-names>AC</given-names></name></person-group><article-title>The microcirculation and lymphatic system: capillary fluid exchange, interstitial fluid, and lymph flow</article-title><source>Guyton and Hall: Textbook of Medical Physiology</source><year>2011</year><publisher-loc>Philadelphia</publisher-loc><publisher-name>Saunders, Elsevier</publisher-name><fpage>177</fpage><lpage>190</lpage><comment>ed..</comment></element-citation></ref><ref id="b8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levick</surname><given-names>JR</given-names></name></person-group><person-group person-group-type="author"><name><surname>Michel</surname><given-names>CC</given-names></name></person-group><article-title>Microvascular fluid exchange and the revised Starling principle</article-title><source>Cardiovasc. Res</source><year>2010</year><volume>87</volume><fpage>198</fpage><lpage>210</lpage><comment>and</comment><pub-id pub-id-type="pmid">20200043</pub-id></element-citation></ref><ref id="b9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohtani</surname><given-names>O</given-names></name><name><surname>Ohtani</surname><given-names>Y</given-names></name><name><surname>Carati</surname><given-names>CJ</given-names></name></person-group><person-group person-group-type="author"><name><surname>Gannon</surname><given-names>BJ</given-names></name></person-group><article-title>Fluid and cellular pathways of rat lymph nodes in relation to lymphatic labyrinths and Aquaporin-1 expression</article-title><source>Arch. Histol. Cytol</source><year>2003</year><volume>66</volume><fpage>261</fpage><lpage>272</lpage><comment>and</comment><pub-id pub-id-type="pmid">14527167</pub-id></element-citation></ref><ref id="b10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>PA</given-names></name><name><surname>Franks</surname><given-names>PJ</given-names></name></person-group><person-group person-group-type="author"><name><surname>Moffatt</surname><given-names>CJ</given-names></name></person-group><article-title>Health-related quality of life with lymphoedema: a review of the literature</article-title><source>Int. Wound J</source><year>2005</year><volume>2</volume><fpage>47</fpage><lpage>62</lpage><comment>and</comment><pub-id pub-id-type="pmid">16722853</pub-id></element-citation></ref><ref id="b11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>MG</given-names></name><name><surname>Dagenais</surname><given-names>SL</given-names></name><name><surname>Rockson</surname><given-names>SG</given-names></name></person-group><person-group person-group-type="author"><name><surname>Glover</surname><given-names>TW</given-names></name></person-group><article-title>A novel VEGFR3 mutation causes Milroy disease</article-title><source>Am. J. Med. Genet. A</source><year>2007</year><volume>143A</volume><fpage>1212</fpage><lpage>1217</lpage><comment>and</comment><pub-id pub-id-type="pmid">17458866</pub-id></element-citation></ref><ref id="b12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>AG</given-names></name><name><surname>Brorson</surname><given-names>H</given-names></name><name><surname>Borud</surname><given-names>LJ</given-names></name></person-group><person-group person-group-type="author"><name><surname>Slavin</surname><given-names>SA</given-names></name></person-group><article-title>Lymphedema: a comprehensive review</article-title><source>Ann. Plast. Surg</source><year>2007</year><volume>59</volume><fpage>464</fpage><lpage>472</lpage><comment>and</comment><pub-id pub-id-type="pmid">17901744</pub-id></element-citation></ref><ref id="b13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfarr</surname><given-names>KM</given-names></name><name><surname>Debrah</surname><given-names>AY</given-names></name><name><surname>Specht</surname><given-names>S</given-names></name></person-group><person-group person-group-type="author"><name><surname>Hoerauf</surname><given-names>A</given-names></name></person-group><article-title>Filariasis and lymphoedema</article-title><source>Parasite Immunol</source><year>2009</year><volume>31</volume><fpage>664</fpage><lpage>672</lpage><comment>and</comment><pub-id pub-id-type="pmid">19825106</pub-id></element-citation></ref><ref id="b14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>JI</given-names></name><name><surname>Riedel</surname><given-names>ER</given-names></name><name><surname>Morrow</surname><given-names>M</given-names></name></person-group><person-group person-group-type="author"><name><surname>Van Zee</surname><given-names>KJ</given-names></name></person-group><article-title>Morbidity of sentinel node biopsy: relationship between number of excised lymph nodes and patient perceptions of lymphedema</article-title><source>Ann. Surg. Oncol</source><year>2011</year><volume>18</volume><fpage>2866</fpage><lpage>2872</lpage><comment>and</comment><pub-id pub-id-type="pmid">21465310</pub-id></element-citation></ref><ref id="b15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>AF</given-names></name><name><surname>Franks</surname><given-names>PJ</given-names></name></person-group><person-group person-group-type="author"><name><surname>Moffatt</surname><given-names>CJ</given-names></name></person-group><article-title>Lymphoedema: estimating the size of the problem</article-title><source>Palliat. Med</source><year>2005</year><volume>19</volume><fpage>300</fpage><lpage>313</lpage><comment>and</comment><pub-id pub-id-type="pmid">15984502</pub-id></element-citation></ref><ref id="b16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mortimer</surname><given-names>P</given-names></name></person-group><article-title>Arm lymphoedema after breast cancer</article-title><source>Lancet Oncol</source><year>2013</year><volume>14</volume><fpage>442</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">23540560</pub-id></element-citation></ref><ref id="b17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrell</surname><given-names>RE</given-names></name><name><surname>Baty</surname><given-names>CJ</given-names></name><name><surname>Kimak</surname><given-names>MA</given-names></name><name><surname>Karlsson</surname><given-names>JM</given-names></name><name><surname>Lawrence</surname><given-names>EC</given-names></name><name><surname>Franke-Snyder</surname><given-names>M</given-names></name><name><surname>Meriney</surname><given-names>SD</given-names></name><name><surname>Feingold</surname><given-names>E</given-names></name></person-group><person-group person-group-type="author"><name><surname>Finegold</surname><given-names>DN</given-names></name></person-group><article-title>MAGJC2 missense mutations cause human lymphedema</article-title><source>Am. J. Hum. Genet</source><year>2010</year><volume>86</volume><fpage>943</fpage><lpage>948</lpage><comment>and</comment><pub-id pub-id-type="pmid">20537300</pub-id></element-citation></ref><ref id="b18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finegold</surname><given-names>DN</given-names></name><name><surname>Baty</surname><given-names>CJ</given-names></name><name><surname>Knickelbein</surname><given-names>KZ</given-names></name><name><surname>Perschke</surname><given-names>S</given-names></name><name><surname>Noon</surname><given-names>SE</given-names></name><name><surname>Campbell</surname><given-names>D</given-names></name><name><surname>Karlsson</surname><given-names>JM</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Kimak</surname><given-names>MA</given-names></name><name><surname>Lawrence</surname><given-names>EC</given-names></name></person-group><article-title>Connexin 47 mutations increase risk for secondary lymphedema following breast cancer treatment</article-title><source>Clin. Cancer Res</source><year>2012</year><volume>18</volume><fpage>2382</fpage><lpage>2390</lpage><comment>et al.</comment><pub-id pub-id-type="pmid">22351697</pub-id></element-citation></ref><ref id="b19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>G</given-names></name><name><surname>Baggott</surname><given-names>C</given-names></name><name><surname>West</surname><given-names>C</given-names></name><name><surname>Elboim</surname><given-names>C</given-names></name><name><surname>Paul</surname><given-names>SM</given-names></name><name><surname>Cooper</surname><given-names>BA</given-names></name><name><surname>Abrams</surname><given-names>G</given-names></name><name><surname>Dhruva</surname><given-names>A</given-names></name><name><surname>Schmidt</surname><given-names>BL</given-names></name><name><surname>Kober</surname><given-names>K</given-names></name></person-group><article-title>Cytokine candidate genes predict the development of secondary lymphedema following breast cancer surgery</article-title><source>Lymphat. Res. Biol</source><year>2014</year><volume>12</volume><fpage>10</fpage><lpage>22</lpage><comment>et al.</comment><pub-id pub-id-type="pmid">24502445</pub-id></element-citation></ref><ref id="b20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Roche</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>NL</given-names></name><name><surname>Tsao</surname><given-names>PS</given-names></name></person-group><person-group person-group-type="author"><name><surname>Rockson</surname><given-names>SG</given-names></name></person-group><article-title>Prospective transcriptomic pathway analysis of human lymphatic vascular insufficiency: identification and validation of a circulating biomarker panel</article-title><source>PLoS. One</source><year>2012</year><volume>7</volume><fpage>e52021</fpage><comment>and</comment><pub-id pub-id-type="pmid">23272198</pub-id></element-citation></ref><ref id="b21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>B</given-names></name><name><surname>Lose</surname><given-names>F</given-names></name><name><surname>Kedda</surname><given-names>MA</given-names></name><name><surname>Francois</surname><given-names>M</given-names></name><name><surname>Ferguson</surname><given-names>K</given-names></name><name><surname>Janda</surname><given-names>M</given-names></name><name><surname>Yates</surname><given-names>P</given-names></name></person-group><person-group person-group-type="author"><name><surname>Spurdle</surname><given-names>AB</given-names></name></person-group><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>SC</given-names></name></person-group><article-title>Possible genetic predisposition to lymphedema after breast cancer</article-title><source>Lymphat. Res. Biol</source><year>2012</year><volume>10</volume><fpage>2</fpage><lpage>13</lpage><comment>and</comment><pub-id pub-id-type="pmid">22404826</pub-id></element-citation></ref><ref id="b22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiSipio</surname><given-names>T</given-names></name><name><surname>Rye</surname><given-names>S</given-names></name><name><surname>Newman</surname><given-names>B</given-names></name></person-group><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>S</given-names></name></person-group><article-title>Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis</article-title><source>Lancet Oncol</source><year>2013</year><volume>14</volume><fpage>500</fpage><lpage>515</lpage><comment>and</comment><pub-id pub-id-type="pmid">23540561</pub-id></element-citation></ref><ref id="b23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehrara</surname><given-names>BJ</given-names></name><name><surname>Zampell</surname><given-names>JC</given-names></name><name><surname>Suami</surname><given-names>H</given-names></name></person-group><person-group person-group-type="author"><name><surname>Chang</surname><given-names>DW</given-names></name></person-group><article-title>Surgical management of lymphedema: past, present, and future</article-title><source>Lymphat. Res. Biol</source><year>2011</year><volume>9</volume><fpage>159</fpage><lpage>167</lpage><comment>and</comment><pub-id pub-id-type="pmid">22066746</pub-id></element-citation></ref><ref id="b24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suami</surname><given-names>H</given-names></name></person-group><person-group person-group-type="author"><name><surname>Chang</surname><given-names>DW</given-names></name></person-group><article-title>Overview of surgical treatments for breast cancer-related lymphedema</article-title><source>Plast. Reconstr. Surg</source><year>2010</year><volume>126</volume><fpage>1853</fpage><lpage>1863</lpage><comment>and</comment><pub-id pub-id-type="pmid">21124127</pub-id></element-citation></ref><ref id="b25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cormier</surname><given-names>JN</given-names></name><name><surname>Rourke</surname><given-names>L</given-names></name><name><surname>Crosby</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>D</given-names></name></person-group><person-group person-group-type="author"><name><surname>Armer</surname><given-names>J</given-names></name></person-group><article-title>The surgical treatment of lymphedema: a systematic review of the contemporary literature (2004–2010)</article-title><source>Ann. Surg. Oncol</source><year>2012</year><volume>19</volume><fpage>642</fpage><lpage>651</lpage><comment>and</comment><pub-id pub-id-type="pmid">21863361</pub-id></element-citation></ref><ref id="b26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vignes</surname><given-names>S</given-names></name><name><surname>Blanchard</surname><given-names>M</given-names></name><name><surname>Yannoutsos</surname><given-names>A</given-names></name></person-group><person-group person-group-type="author"><name><surname>Arrault</surname><given-names>M</given-names></name></person-group><article-title>Complications of autologous lymph-node transplantation for limb lymphoedema</article-title><source>Eur. J. Vasc. Endovasc. Surg</source><year>2013</year><volume>45</volume><fpage>516</fpage><lpage>520</lpage><comment>and</comment><pub-id pub-id-type="pmid">23305787</pub-id></element-citation></ref><ref id="b27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brorson</surname><given-names>H</given-names></name></person-group><article-title>From lymph to fat: liposuction as a treatment for complete reduction of lymphedema</article-title><source>Int. J. Low Extrem. Wounds</source><year>2012</year><volume>11</volume><fpage>10</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">22363050</pub-id></element-citation></ref><ref id="b28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blum</surname><given-names>KS</given-names></name><name><surname>Hadamitzky</surname><given-names>C</given-names></name><name><surname>Gratz</surname><given-names>KF</given-names></name></person-group><person-group person-group-type="author"><name><surname>Pabst</surname><given-names>R</given-names></name></person-group><article-title>Effects of autotransplanted lymph node fragments on the lymphatic system in the pig model</article-title><source>Breast Cancer Res. Treat</source><year>2010</year><volume>120</volume><fpage>59</fpage><lpage>66</lpage><comment>and</comment><pub-id pub-id-type="pmid">19301120</pub-id></element-citation></ref><ref id="b29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pabst</surname><given-names>R</given-names></name></person-group><person-group person-group-type="author"><name><surname>Rothkotter</surname><given-names>HJ</given-names></name></person-group><article-title>Regeneration of autotransplanted lymph node fragments</article-title><source>Cell Tissue Res</source><year>1988</year><volume>251</volume><fpage>597</fpage><lpage>601</lpage><comment>and</comment><pub-id pub-id-type="pmid">3270994</pub-id></element-citation></ref><ref id="b30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothkotter</surname><given-names>HJ</given-names></name></person-group><person-group person-group-type="author"><name><surname>Pabst</surname><given-names>R</given-names></name></person-group><article-title>Autotransplantation of lymph node fragments. Structure and function of regenerated tissue</article-title><source>Scand. J. Plast. Reconstr. Surg. Hand Surg</source><year>1990</year><volume>24</volume><fpage>101</fpage><lpage>105</lpage><comment>and</comment><pub-id pub-id-type="pmid">2237306</pub-id></element-citation></ref><ref id="b31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tammela</surname><given-names>T</given-names></name><name><surname>Saaristo</surname><given-names>A</given-names></name><name><surname>Holopainen</surname><given-names>T</given-names></name><name><surname>Lyytikkä</surname><given-names>J</given-names></name><name><surname>Kotronen</surname><given-names>A</given-names></name><name><surname>Pitkonen</surname><given-names>M</given-names></name><name><surname>Abo-Ramadan</surname><given-names>U</given-names></name><name><surname>Ylä-Herttuala</surname><given-names>S</given-names></name><name><surname>Petrova</surname><given-names>TV</given-names></name></person-group><person-group person-group-type="author"><name><surname>Alitalo</surname><given-names>K</given-names></name></person-group><article-title>Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation</article-title><source>Nat.Med</source><year>2007</year><volume>13</volume><fpage>1458</fpage><lpage>1466</lpage><comment>and</comment><pub-id pub-id-type="pmid">18059280</pub-id></element-citation></ref><ref id="b32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobbia</surname><given-names>D</given-names></name><name><surname>Semple</surname><given-names>J</given-names></name><name><surname>Baker</surname><given-names>A</given-names></name><name><surname>Dumont</surname><given-names>D</given-names></name></person-group><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>M</given-names></name></person-group><article-title>Experimental assessment of autologous lymph node transplantation as treatment of postsurgical lymphedema</article-title><source>Plast. Reconstr. Surg</source><year>2009</year><volume>124</volume><fpage>777</fpage><lpage>786</lpage><comment>and</comment><pub-id pub-id-type="pmid">19730296</pub-id></element-citation></ref><ref id="b33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sommer</surname><given-names>T</given-names></name><name><surname>Buettner</surname><given-names>M</given-names></name><name><surname>Bruns</surname><given-names>F</given-names></name><name><surname>Breves</surname><given-names>G</given-names></name><name><surname>Hadamitzky</surname><given-names>C</given-names></name></person-group><person-group person-group-type="author"><name><surname>Pabst</surname><given-names>R</given-names></name></person-group><article-title>Improved regeneration of autologous transplanted lymph node fragments by VEGF-C treatment</article-title><source>Anat. Rec. (Hoboken.)</source><year>2012</year><volume>295</volume><fpage>786</fpage><lpage>791</lpage><comment>and</comment><pub-id pub-id-type="pmid">22419614</pub-id></element-citation></ref><ref id="b34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sommer</surname><given-names>T</given-names></name><name><surname>Meier</surname><given-names>M</given-names></name><name><surname>Bruns</surname><given-names>F</given-names></name><name><surname>Pabst</surname><given-names>R</given-names></name><name><surname>Breves</surname><given-names>G</given-names></name></person-group><person-group person-group-type="author"><name><surname>Hadamitzky</surname><given-names>C</given-names></name></person-group><article-title>Quantification of lymphedema in a rat model by 3D-active contour segmentation by magnetic resonance imaging</article-title><source>Lymphat. Res. Biol</source><year>2012</year><volume>10</volume><fpage>25</fpage><lpage>29</lpage><comment>and</comment><pub-id pub-id-type="pmid">22416909</pub-id></element-citation></ref><ref id="b35"><label>35</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Schindewolffs</surname><given-names>L</given-names></name></person-group><year>2012</year><comment>. Die Transplantation autologer Lymphknotenfragmente als Therapiemöglichkeit des sekundären Lymphödems. Inaugural dissertation Dr. med.vet., Tierärztliche Hochschule Hannover. Tierärztliche Hochschule Hannover</comment></element-citation></ref><ref id="b36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burton</surname><given-names>JB</given-names></name><name><surname>Priceman</surname><given-names>SJ</given-names></name><name><surname>Sung</surname><given-names>JL</given-names></name><name><surname>Brakenhielm</surname><given-names>E</given-names></name><name><surname>An</surname><given-names>DS</given-names></name><name><surname>Pytowski</surname><given-names>B</given-names></name><name><surname>Alitalo</surname><given-names>K</given-names></name></person-group><person-group person-group-type="author"><name><surname>Wu</surname><given-names>L</given-names></name></person-group><article-title>Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis</article-title><source>Cancer Res</source><year>2008</year><volume>68</volume><fpage>7828</fpage><lpage>7837</lpage><comment>and</comment><pub-id pub-id-type="pmid">18829538</pub-id></element-citation></ref><ref id="b37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alitalo</surname><given-names>K</given-names></name><name><surname>Tammela</surname><given-names>T</given-names></name></person-group><person-group person-group-type="author"><name><surname>Petrova</surname><given-names>TV</given-names></name></person-group><article-title>Lymphangiogenesis in development and human disease</article-title><source>Nature</source><year>2005</year><volume>438</volume><fpage>946</fpage><lpage>953</lpage><comment>and</comment><pub-id pub-id-type="pmid">16355212</pub-id></element-citation></ref><ref id="b38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liersch</surname><given-names>R</given-names></name><name><surname>Hirakawa</surname><given-names>S</given-names></name><name><surname>Berdel</surname><given-names>WE</given-names></name><name><surname>Mesters</surname><given-names>RM</given-names></name></person-group><person-group person-group-type="author"><name><surname>Detmar</surname><given-names>M</given-names></name></person-group><article-title>Induced lymphatic sinus hyperplasia in sentinel lymph nodes by VEGF-C as the earliest premetastatic indicator</article-title><source>Int. J. Oncol</source><year>2012</year><volume>41</volume><fpage>2073</fpage><lpage>2078</lpage><comment>and</comment><pub-id pub-id-type="pmid">23076721</pub-id></element-citation></ref><ref id="b39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>XZ</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>XH</given-names></name></person-group><person-group person-group-type="author"><name><surname>Cao</surname><given-names>XC</given-names></name></person-group><article-title>A retrospective study of different local treatments in breast cancer patients with synchronous ipsilateral supraclavicular lymph node metastasis</article-title><source>J. Cancer Res. Ther</source><year>2013</year><fpage>S158</fpage><lpage>S161</lpage><comment>and (9 Suppl):</comment><pub-id pub-id-type="pmid">24516053</pub-id></element-citation></ref><ref id="b40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dominick</surname><given-names>SA</given-names></name><name><surname>Madlensky</surname><given-names>L</given-names></name><name><surname>Natarajan</surname><given-names>L</given-names></name></person-group><person-group person-group-type="author"><name><surname>Pierce</surname><given-names>JP</given-names></name></person-group><article-title>Risk factors associated with breast cancer-related lymphedema in the WHEL Study</article-title><source>J. Cancer Surviv</source><year>2013</year><volume>7</volume><fpage>115</fpage><lpage>123</lpage><comment>and</comment><pub-id pub-id-type="pmid">23212606</pub-id></element-citation></ref><ref id="b41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ul-Mulk</surname><given-names>J</given-names></name></person-group><person-group person-group-type="author"><name><surname>Holmich</surname><given-names>LR</given-names></name></person-group><article-title>Lymph node dissection in patients with malignant melanoma is associated with high risk of morbidity</article-title><source>Dan. Med. J</source><year>2012</year><volume>59</volume><fpage>A4441</fpage><comment>and</comment><pub-id pub-id-type="pmid">22677239</pub-id></element-citation></ref><ref id="b42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabson</surname><given-names>JA</given-names></name><name><surname>Geyer</surname><given-names>SJ</given-names></name><name><surname>Levine</surname><given-names>G</given-names></name><name><surname>Swartz</surname><given-names>WM</given-names></name></person-group><person-group person-group-type="author"><name><surname>Futrell</surname><given-names>JW</given-names></name></person-group><article-title>Tumor immunity in rat lymph nodes following transplantation</article-title><source>Ann. Surg</source><year>1982</year><volume>196</volume><fpage>92</fpage><lpage>99</lpage><comment>and</comment><pub-id pub-id-type="pmid">7092359</pub-id></element-citation></ref><ref id="b43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turnbull</surname><given-names>C</given-names></name><name><surname>Ahmed</surname><given-names>S</given-names></name><name><surname>Morrison</surname><given-names>J</given-names></name><name><surname>Pernet</surname><given-names>D</given-names></name><name><surname>Renwick</surname><given-names>A</given-names></name><name><surname>Maranian</surname><given-names>M</given-names></name><name><surname>Seal</surname><given-names>S</given-names></name><name><surname>Ghoussaini</surname><given-names>M</given-names></name><name><surname>Hines</surname><given-names>S</given-names></name><name><surname>Healey</surname><given-names>CS</given-names></name><name><surname>Hughes</surname><given-names>D</given-names></name><name><surname>Warren-Perry</surname><given-names>M</given-names></name><name><surname>Tapper</surname><given-names>W</given-names></name><name><surname>Eccles</surname><given-names>D</given-names></name><name><surname>Evans</surname><given-names>DG</given-names></name></person-group><collab>Breast Cancer Susceptibility Collaboration (UK)</collab><person-group person-group-type="author"><name><surname>Hooning</surname><given-names>M</given-names></name><name><surname>Schutte</surname><given-names>M</given-names></name><name><surname>van den Ouweland</surname><given-names>A</given-names></name><name><surname>Houlston</surname><given-names>R</given-names></name><name><surname>Ross</surname><given-names>G</given-names></name><name><surname>Langford</surname><given-names>C</given-names></name><name><surname>Pharoah</surname><given-names>PD</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Dunning</surname><given-names>AM</given-names></name><name><surname>Rahman</surname><given-names>N</given-names></name></person-group><person-group person-group-type="author"><name><surname>Easton</surname><given-names>DF</given-names></name></person-group><article-title>Genome-wide association study identifies five new breast cancer susceptibility loci</article-title><source>Nat. Genet</source><year>2010</year><volume>42</volume><fpage>504</fpage><lpage>507</lpage><comment>and</comment><pub-id pub-id-type="pmid">20453838</pub-id></element-citation></ref><ref id="b44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadamitzky</surname><given-names>C</given-names></name><name><surname>Blum</surname><given-names>KS</given-names></name></person-group><person-group person-group-type="author"><name><surname>Pabst</surname><given-names>R</given-names></name></person-group><article-title>Regeneration of autotransplanted avascular lymph nodes in the rat is improved by platelet-rich plasma</article-title><source>J. Vasc. Res</source><year>2009</year><volume>46</volume><fpage>389</fpage><lpage>396</lpage><comment>and</comment><pub-id pub-id-type="pmid">19155630</pub-id></element-citation></ref><ref id="b45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lohela</surname><given-names>M</given-names></name><name><surname>Saaristo</surname><given-names>A</given-names></name><name><surname>Veikkola</surname><given-names>T</given-names></name></person-group><person-group person-group-type="author"><name><surname>Alitalo</surname><given-names>K</given-names></name></person-group><article-title>Lymphangiogenic growth factors, receptors and therapies</article-title><source>Thromb. Haemost</source><year>2003</year><volume>90</volume><fpage>167</fpage><lpage>184</lpage><comment>and</comment><pub-id pub-id-type="pmid">12888864</pub-id></element-citation></ref><ref id="b46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pezner</surname><given-names>RD</given-names></name><name><surname>Patterson</surname><given-names>MP</given-names></name><name><surname>Hill</surname><given-names>LR</given-names></name><name><surname>Lipsett</surname><given-names>JA</given-names></name><name><surname>Desai</surname><given-names>KR</given-names></name><name><surname>Vora</surname><given-names>N</given-names></name><name><surname>Wong</surname><given-names>JY</given-names></name></person-group><person-group person-group-type="author"><name><surname>Luk</surname><given-names>KH</given-names></name></person-group><article-title>Arm lymphedema in patients treated conservatively for breast cancer: relationship to patient age and axillary node dissection technique</article-title><source>Int. J. Radiat. Oncol. Biol. Phys</source><year>1986</year><volume>12</volume><fpage>2079</fpage><lpage>2083</lpage><comment>and</comment><pub-id pub-id-type="pmid">3793544</pub-id></element-citation></ref><ref id="b47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadamitzky</surname><given-names>C</given-names></name><name><surname>Spohr</surname><given-names>H</given-names></name><name><surname>Debertin</surname><given-names>AS</given-names></name><name><surname>Guddat</surname><given-names>S</given-names></name><name><surname>Tsokos</surname><given-names>M</given-names></name></person-group><person-group person-group-type="author"><name><surname>Pabst</surname><given-names>R</given-names></name></person-group><article-title>Age-dependent histoarchitectural changes in human lymph nodes: an underestimated process with clinical relevance</article-title><source>J. Anat</source><year>2010</year><volume>216</volume><fpage>556</fpage><lpage>562</lpage><comment>and</comment><pub-id pub-id-type="pmid">20345860</pub-id></element-citation></ref><ref id="b48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avraham</surname><given-names>T</given-names></name><name><surname>Clavin</surname><given-names>NW</given-names></name><name><surname>Daluvoy</surname><given-names>SV</given-names></name><name><surname>Fernandez</surname><given-names>J</given-names></name><name><surname>Soares</surname><given-names>MA</given-names></name><name><surname>Cordeiro</surname><given-names>AP</given-names></name></person-group><person-group person-group-type="author"><name><surname>Mehrara</surname><given-names>BJ</given-names></name></person-group><article-title>Fibrosis is a key inhibitor of lymphatic regeneration</article-title><source>Plast. Reconstr. Surg</source><year>2009</year><volume>124</volume><fpage>438</fpage><lpage>450</lpage><comment>and</comment><pub-id pub-id-type="pmid">19644258</pub-id></element-citation></ref><ref id="b49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couto</surname><given-names>RA</given-names></name><name><surname>Kulungowski</surname><given-names>AM</given-names></name><name><surname>Chawla</surname><given-names>AS</given-names></name><name><surname>Fishman</surname><given-names>SJ</given-names></name></person-group><person-group person-group-type="author"><name><surname>Greene</surname><given-names>AK</given-names></name></person-group><article-title>Expression of angiogenic and vasculogenic factors in human lymphedematous tissue</article-title><source>Lymphat. Res. Biol</source><year>2011</year><volume>9</volume><fpage>143</fpage><lpage>149</lpage><comment>and</comment><pub-id pub-id-type="pmid">22066744</pub-id></element-citation></ref><ref id="b50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogata</surname><given-names>F</given-names></name><name><surname>Narushima</surname><given-names>M</given-names></name><name><surname>Mihara</surname><given-names>M</given-names></name><name><surname>Azuma</surname><given-names>R</given-names></name><name><surname>Morimoto</surname><given-names>Y</given-names></name></person-group><person-group person-group-type="author"><name><surname>Koshima</surname><given-names>I</given-names></name></person-group><article-title>Intraoperative lymphography using indocyanine green dye for near-infrared fluorescence labeling in lymphedema</article-title><source>Ann. Plast. Surg</source><year>2007</year><volume>59</volume><fpage>180</fpage><lpage>184</lpage><comment>and</comment><pub-id pub-id-type="pmid">17667413</pub-id></element-citation></ref><ref id="b51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polom</surname><given-names>K</given-names></name><name><surname>Murawa</surname><given-names>D</given-names></name><name><surname>Rho</surname><given-names>YS</given-names></name><name><surname>Nowaczyk</surname><given-names>P</given-names></name><name><surname>Hunerbein</surname><given-names>M</given-names></name></person-group><person-group person-group-type="author"><name><surname>Murawa</surname><given-names>P</given-names></name></person-group><article-title>Current trends and emerging future of indocyanine green usage in surgery and oncology: a literature review</article-title><source>Cancer</source><year>2011</year><volume>117</volume><fpage>4812</fpage><lpage>4822</lpage><comment>and</comment><pub-id pub-id-type="pmid">21484779</pub-id></element-citation></ref><ref id="b52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serizawa</surname><given-names>F</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Matsubara</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>A</given-names></name><name><surname>Shimokawa</surname><given-names>H</given-names></name></person-group><person-group person-group-type="author"><name><surname>Satomi</surname><given-names>S</given-names></name></person-group><article-title>Extracorporeal shock wave therapy induces therapeutic lymphangiogenesis in a rat model of secondary lymphoedema</article-title><source>Eur. J. Vasc. Endovasc. Surg</source><year>2011</year><volume>42</volume><fpage>254</fpage><lpage>260</lpage><comment>and</comment><pub-id pub-id-type="pmid">21454105</pub-id></element-citation></ref></ref-list><sec sec-type="supplementary-material"><title>Supporting Information</title><p>Additional supporting information may be found in the online version of this article at the publisher's web-site.</p><supplementary-material content-type="local-data" id="sd1"><caption><p><bold>Figure S1.</bold> Surgical procedure. (A) The subcutaneous tissue was punctured. (B) The three harvested lymph nodes got (C) stringed to the needle and suture and (D) the subcutaneous tissue was punctured again. (E) Due to the surgical technique the transplants lay on a subcutaneous tissue bridge and therefore (F) the knot is separated from the transplants by subcutaneous tissue.</p><p><bold>Figure S2.</bold> Transplantation area during sampling.</p></caption><media mimetype="docx" mime-subtype="docx" xlink:href="iid30002-0152-sd1.docx" xlink:type="simple" id="d35e3201" position="anchor"></media></supplementary-material></sec></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003F02 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 003F02 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.31. |  |